Brain (and spinal cord) tumours
Open
Phase 1/2
This trial is looking at avutometinib and defactinib for glioblastoma.
It is for people whose brain tumours have come back or the last treatment didn’t work.
You pronounce avutometinib as a-voo-toe-me-ti-nib. You pronounce defactinib as dee-fak-ti-nib.
The 5G-RUBY trial is part of a large research programme looking at new treatments for brain tumours. The research programme is called the 5G: A next-Generation aGile Genomically Guided Glioma platform trial. It’s called the 5G platform trial for short.
Cancer Research UK supports this trial.
Recruitment start: 1 October 2024
Recruitment end: 31 January 2029
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Juanita Lopez
Institute of Cancer Research (ICR)
Cancer Research UK
Minderoo Foundation
Verastem Inc
Royal Marsden NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust
University of Cambridge
This is Cancer Research UK trial number CRUK/23/004.
Last reviewed: 26 Nov 2025
CRUK internal database number: 20139
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
